万孚生物(300482) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥2,625,283,985.42, representing a 276.87% increase compared to ¥696,605,661.68 in the same period last year[3] - Net profit attributable to shareholders was ¥903,506,781.16, up 481.32% from ¥155,422,449.02 year-on-year[3] - The basic earnings per share increased to ¥2.05, a rise of 485.71% from ¥0.35 in the previous year[3] - Total operating revenue for the current period reached ¥2,625,283,985.42, a significant increase from ¥696,605,661.68 in the previous period, representing a growth of approximately 276.5%[27] - Net profit for the current period was ¥901,709,729.58, compared to ¥152,445,830.45 in the previous period, reflecting a growth of approximately 490.5%[30] - Total profit for the current period was ¥1,047,858,338.29, up from ¥175,801,864.28, indicating a growth of about 496.5%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,644,864,052.58, reflecting a 36.84% increase from ¥4,855,824,467.37 at the end of the previous year[3] - Total current assets amounted to CNY 4,130.55 million, compared to CNY 2,585.51 million at the beginning of the year[19] - Total liabilities reached CNY 2,226.17 million, up from CNY 1,351.75 million at the beginning of the year[23] - The total assets of the company stood at CNY 6,644.86 million, compared to CNY 4,855.82 million at the beginning of the year[19] Cash Flow - The company reported a net cash flow from operating activities of -¥357,477,956.88, a decrease of 1,856.83% compared to the previous year[3] - Cash inflow from operating activities totaled ¥1,203,610,658.01, compared to ¥619,354,290.97 in the previous period, representing an increase of approximately 94.3%[33] - Cash outflow from investment activities was $2.00 billion, a decrease from $2.17 billion in the previous period[36] - Cash received from borrowings was $206.94 million, a substantial increase from $8.73 million in the prior period[36] Inventory and Receivables - Accounts receivable increased by 312.68% to ¥2,056,463,191.15, driven by higher sales revenue[7] - Inventory levels rose by 96.35% to ¥758,368,486.69, attributed to increased stockpiling for COVID-19[7] - The company’s inventory increased to CNY 758.37 million from CNY 386.24 million at the beginning of the year[19] Research and Development - Research and development expenses rose to ¥118,277,455.31 from ¥82,637,137.61, an increase of approximately 43.2%[27] COVID-19 Products - The company has obtained CE certification for its COVID-19 antigen self-test products and has received approval in countries including Brazil, Russia, Australia, Thailand, Malaysia, and Myanmar[15] - The company’s COVID-19 testing products are now sold in over 100 countries and regions across Europe, Asia, Latin America, and the Middle East[15] - The company reported a significant increase in revenue from COVID-19 testing products due to its support for pandemic control efforts in Hong Kong[15]